Clinical Trial Update: Clinical Trial to Assess the Efficacy and Toxicity of Induction and Consolidation With CPX-351 for Patients Aged 60 to 75 Years With Secondary or High-risk Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial assessing CPX-351 for induction/consolidation in older adults with secondary or high-risk acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CPX-351 (liposomal daunorubicin/cytarabine)

Snippet

Sponsor: PETHEMA Foundation | Conditions: Newly Diagnosed Secondary or High Risk AML | Phase 2 | Status: COMPLETED